The virulence of Pseudomonas aeruginosa
- PMID: 6443764
- DOI: 10.1093/clinids/6.supplement_3.s617
The virulence of Pseudomonas aeruginosa
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen whose adaptability, ubiquitousness, and pathogenicity are closely related. Both cell-associated and extracellular products of P. aeruginosa contribute to its virulence. Surface structures, including pili and the polysaccharide capsule or glycocalyx, appear to mediate the initial attachment of P. aeruginosa to its prospective host, thus permitting colonization. Extracellular enzymes such as alkaline protease, elastase, phospholipase C, and exotoxin A degrade infected tissues and promote bacterial invasion. When dissemination occurs, systemic disease results, often with fatal consequences. Although extracellular enzymes of P. aeruginosa figure prominently in local disease processes, exotoxin A and endotoxin are primarily responsible for systemic disease. The most protective antibodies presently known are directed toward the nontoxic portions of P. aeruginosa lipopolysaccharides that serve no known virulence function per se. However, there is preliminary evidence that the protective activity of these opsonic antibodies may be augmented by toxin-neutralizing antibodies directed toward the lipid A moiety of endotoxin and exotoxin A.
Similar articles
-
Pseudomonas aeruginosa antigens as potential vaccines.FEMS Microbiol Rev. 1997 Nov;21(3):243-77. doi: 10.1111/j.1574-6976.1997.tb00353.x. FEMS Microbiol Rev. 1997. PMID: 9451816 Review.
-
Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology.J Pediatr. 1986 May;108(5 Pt 2):800-5. doi: 10.1016/s0022-3476(86)80748-x. J Pediatr. 1986. PMID: 3009772
-
Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.J Infect Dis. 1983 Jun;147(6):1090-8. doi: 10.1093/infdis/147.6.1090. J Infect Dis. 1983. PMID: 6406615
-
Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.Infect Immun. 2001 Apr;69(4):2223-9. doi: 10.1128/IAI.69.4.2223-2229.2001. Infect Immun. 2001. PMID: 11254577 Free PMC article.
-
Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.Biopolymers. 2003;71(2):141-68. doi: 10.1002/bip.10395. Biopolymers. 2003. PMID: 12767116 Review.
Cited by
-
Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.PLoS One. 2010 May 20;5(5):e10744. doi: 10.1371/journal.pone.0010744. PLoS One. 2010. PMID: 20505762 Free PMC article.
-
Production of leukotriene B4 and 5-hydroxyeicosatetraenoic acid by human neutrophils is inhibited by Pseudomonas aeruginosa phenazine derivatives.Infect Immun. 1991 Sep;59(9):3316-8. doi: 10.1128/iai.59.9.3316-3318.1991. Infect Immun. 1991. PMID: 1652564 Free PMC article.
-
Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.Infect Immun. 1986 Sep;53(3):656-62. doi: 10.1128/iai.53.3.656-662.1986. Infect Immun. 1986. PMID: 2427453 Free PMC article.
-
Production of cell-cell signalling molecules by bacteria isolated from human chronic wounds.J Appl Microbiol. 2010 May;108(5):1509-22. doi: 10.1111/j.1365-2672.2009.04554.x. Epub 2009 Sep 21. J Appl Microbiol. 2010. PMID: 19840177 Free PMC article.
-
Advances in Understanding of the Copper Homeostasis in Pseudomonas aeruginosa.Int J Mol Sci. 2021 Feb 19;22(4):2050. doi: 10.3390/ijms22042050. Int J Mol Sci. 2021. PMID: 33669570 Free PMC article. Review.